新型马尔尼菲篮状菌Mp1p侧向层析检测快速诊断篮状菌病
本研究开发了基于两种靶向马尔尼菲篮状菌特异性蛋白Mp1p的新型单克隆抗体的侧向层析检测(LFA),并在越南5中心239例篮状菌病和160例非篮状菌病晚期HIV住院成人中回顾性评估。LFA尿标本敏感性95.4%,血浆88.7%,特异性均>95%,性能与EIA相当且优于血培养,可在15分钟内无需实验室基础设施完成床旁快速诊断。
要点
- Mp1p LFA尿标本敏感性95.4%,血浆88.7%,特异性均>95%。
- LFA性能与EIA相当,敏感性95.4% vs 97.1%,特异性95.6% vs 97.5%。
- LFA和EIA敏感性均显著优于同期血培养(95.4% vs 97.1% vs 77.8%)。
核心结论
- Mp1p LFA诊断性能优异,与EIA相当,优于血培养,可在15分钟内床旁快速纳入和排除篮状菌病。
研究设计与样本
- 回顾性病例队列研究,从越南5中心晚期HIV住院成人队列中随机选取239例篮状菌病和160例非篮状菌病参与者。
- 以任何临床标本培养确诊篮状菌病为参考标准,在配对血浆和尿标本中评估Mp1p LFA并与验证过的Mp1p EIA比较。
主要发现
- Mp1p LFA分析检测限为400 pg/mL,与EIA相当。
- 与16种常见人类真菌病原体无交叉反应。
- 尿标本临床敏感性高于血浆(95.4% vs 88.7%,P < .01),两种标本临床特异性均>95%。
- LFA与EIA性能相似:敏感性95.4% vs 97.1%(P = .87),特异性95.6% vs 97.5%(P = 1.0)。
- LFA和EIA敏感性均显著高于同期采集的常规血培养(95.4% vs 97.1% vs 77.8%,P < .01)。
临床怎么用
- Mp1p LFA可用于床旁快速诊断篮状菌病,无需实验室基础设施,15分钟内出结果。
- 尿标本敏感性高于血浆,临床可优先考虑尿液检测。
局限性
- 研究为回顾性设计,样本来自晚期HIV住院成人队列,其他人群适用性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis of talaromycosis, a life-threatening invasive fungal disease endemic in Southeast Asia, still relies on protracted culture methods. We report the development and clinical evaluation of a novel lateral flow assay (LFA) for the rapid diagnosis of talaromycosis. METHODS: The LFA used 2 novel monoclonal antibodies targeting the Talaromyces marneffei-specific protein Mp1p. In a retrospective, case-cohort study, we evaluated the diagnostic performance of the Mp1p LFA against the reference standard of culture-proven talaromycosis from any clinical specimens, and compared to our validated Mp1p enzyme immunoassay (EIA) in paired plasma and urine samples from 239 talaromycosis and 160 non-talaromycosis participants randomly selected from cohorts of hospitalized adults with advanced human immunodeficiency virus (HIV) disease from 5 centers across Vietnam. RESULTS: The Mp1p LFA demonstrated an analytical limit-of-detection of 400 pg/mL, comparable to the EIA. No cross-reactivity with 16 common human fungal pathogens was observed. Clinical sensitivity was higher in urine compared to plasma (95.4% vs 88.7%, P < .01), and clinical specificity was >95% in both specimen types. Clinical performance was similar to the EIA: sensitivity 95.4% versus 97.1%, P = .87 and specificity 95.6% versus 97.5%, P =1.0. Both the LFA and EIA were substantially more sensitive than conventional blood culture collected at the same time (95.4% vs 97.1% vs 77.8%, P < .01). CONCLUSIONS: The Mp1p LFA has excellent diagnostic performance, comparable to the EIA, is superior to blood culture, and has the potential to rapidly rule in and rule out talaromycosis at the point-of-care within 15 minutes without need for laboratory infrastructure.
引用
- Thu NTM, Brown L, Hawkins O, et al. Development and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis. Clin Infect Dis. 2026. PMID: 41495935. doi:10.1093/cid/ciag004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。